Companies and research groups pushed forward both diagnostic innovation and execution speed. Illumina launched the MiSeq i100 Series-CN in China, locally manufactured for the domestic market, amid ongoing trade and regulatory constraints that have shaped sequencing availability. On the clinical testing side, Natera emphasized acceleration of prospective Signatera readouts to establish clinical utility for MRD-guided therapy in HR-positive, HER2-negative breast cancer. Executives framed the plan around interventional MRD studies designed to decide when to escalate therapy, betting that prospective evidence can shift practice. Separately, a compact at-home fluorescence device (VPodDuo) was reported as a proof-of-concept for timely molecular testing outside central laboratories. Together, the items show a dual push: more capacity and local manufacturing for core lab platforms, alongside new evidence generation and workflow-friendly testing formats for decentralized care.